Loading...
Loading...
Enanta Pharmaceuticals, Inc.,
ENTA a research and development-focused
biotechnology company dedicated to creating small molecule drugs in the
infectious disease field, today announced that AbbVie, Enanta's development
partner for protease inhibitors for hepatitis C virus (HCV), has initiated a
phase 2b clinical study with ABT-493, Enanta's next-generation protease
inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate
developed within the Enanta-AbbVie collaboration.
The phase 2b study being conducted by AbbVie will evaluate the safety and
efficacy of ABT-493 co-administered with ABT-530, AbbVie's next generation
NS5A inhibitor, in HCV patients. AbbVie has informed Enanta that results from
this trial are expected in 2015 and AbbVie plans to start phase 3 development
of the combination next year. Additional details regarding this study will be
available when they are posted by AbbVie at www.clinicaltrials.gov.
“The goal of our collaboration's next-generation protease inhibitor program is
a pan-genotypic, ribavirin-free, once-daily dosing regimen for HCV patients,”
stated Jay R. Luly, Ph.D., President and CEO.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in